Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review

Woldu, Minyahil Alebachew; Minzi, Omary; Engidawork, Ephrem

doi:10.1007/s40200-020-00552-x

Cited by 13 publications

(20 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning the pattern of ART medication, 48.6% of the participants in our study were on 2NRTIs + 1INSTI regimen, 33.3% on 2NRTIs + 1NNRTI, 17.4% on 2NRTIs + 1PI, and 0.7% on 1NRTI + 1NNRTI + 1INSTI + 1PI regimen. This regimen pattern was similar to a number of other studies [30,47,53]. Besides, the role of ART in the development and progression of CMetS has been elucidated in several other studies, but no signi cant result was obtained in our study [68,75].…”

Section: Discussionsupporting

confidence: 91%

“…In our study the prevalence using the NCEP-2005 de nition was 28.5% (82/288); and it was 43.5% (126/288) using the IDF de nition. A compiled report of studies showed that prevalence of CMetS in HIV infected population was 20.6% using NCEP-2005, and 31.3% using the IDF-2005 [40]. By considering this report as a reference, the chi-square goodness of t test (2X2) result indicated that the prevalence in our study was signi cantly higher by using both the NCEP-2005 (X 2 = 121.94, df = 1, p < 0.001), and the IDF-2005 models (X 2 = 32.99, df = 1, p < 0.001) [40].…”

Section: Discussionmentioning

confidence: 99%

“…A compiled report of studies showed that prevalence of CMetS in HIV infected population was 20.6% using NCEP-2005, and 31.3% using the IDF-2005 [40]. By considering this report as a reference, the chi-square goodness of t test (2X2) result indicated that the prevalence in our study was signi cantly higher by using both the NCEP-2005 (X 2 = 121.94, df = 1, p < 0.001), and the IDF-2005 models (X 2 = 32.99, df = 1, p < 0.001) [40]. However, in comparison to individual study reports, our prevalence falls within the range of previously done studies of [41][42][43][44], and in other aspect, it is a bit higher than the Polish [45], SHIVA (France) [46], Australian [47], South Korean [48], the Ethiopian [8,44,49], and the global meta analysis [50] studies; while it is lower than those reported from Nigeria [51], and China [52].…”

Section: Discussionmentioning

confidence: 99%

“…Where, N (7674) is the total HIV infected population registered for follow-up care and P is the prevalence for CMetS in HIV-infected population obtained from published articles [30]. Considering 10% contingency (lost to follow-up and defaulters), the nal sample size of the study became 314.…”

Section: Sample Size 286mentioning

confidence: 99%

“…Hypothesized % frequency of outcome factor in the population (p): 26%+/-5 [30] Con dence limits as % of 100(absolute +/-%) (d): 5%…”

Section: Sample Size Determinationmentioning

confidence: 99%

See 4 more Smart Citations

Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.

Woldu¹,

Minzi²,

Shibeshi³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background Although marked improvements in life expectancy have been observed with the rapid expansion of Antiretroviral Therapy (ART), Cardiometabolic Syndrome (CMetS) is becoming a serious challenge for People Living with HIV/AIDS (PLWHA). The present study aimed in determining biomarkers and prevalence of CMetS in PLWHA. Methods A hospital-based, observational study was carried out between January 2019 & February 2020 among HIV infected adults (n = 288). Binary logistic regression was used to estimate odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between the outcomes against the predictor variables. Results The current study revealed that the prevalence of CMetS was 28.5% (82/288) using the National Cholesterol Education Program (NCEP)-2005 definition; and it was 43.5% (126/288) using the International Diabetes Federation (IDF)-2005. Male gender was less likely to be associated with CMetS (OR = .086, C.I. 0.025–0.292, p < 0.001) using the NCEP-2005 definition. Individuals with longer duration on ART have an increased odds of CMetS using both the NCEP-2005 (OR = 1.024, C.I. 1.005–1.043, p = 0.014) and the IDF-2005 (OR = 1.251, C.I. 1.061–1.472, p = 0.007) definitions. The age at which ART initiated yet have an impact on the outcomes of CMetS (NCEP-2005: OR = 1.27, C.I. 1.031–1.564, p = 0.025), indicating that individuals who started ART treatment at older age are more likely to have CMetS than their younger counterparts. The study further verified that, individuals with increased waist-grid (central adiposity) were more likely to have CMetS using both the NCEP-2005 (OR = 1.21, C.I. 1.029–1.418, p = 0.021) and the IDF-2005 (OR = 1.730 C.I. 1.454–2.058, p < 0.001) definitions. PLWHA with increased in DBP (OR = 1.164, C.I.1.080–1.254, p < 0.001), Triglyceride (OR = 1.027, C.I. 0.015–0.039, p < 0.001), and low density lipoproteins (OR = 1.075, C.I. 0.020–0.134, p = 0.007) were more likely to have CMetS using the NCEP-2005 definition. PLWHA without comorbidity were less likely to have CMetS (NCEP-2005: OR = 0.086, C.I. 0.025–0.292, p < 0.001). Conclusions The prevalence of CMetS in the study area was high. Risk factors associated with CMetS were waist circumference, gender, duration on ART; ART initiated age, waist-grid, and comorbidity. Biomarkers that were more likely contributed to the prevalence of CMetS include triglyceride, low density lipoproteins, and systolic blood pressure.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Sample Size 286mentioning

confidence: 99%

“…Hypothesized % frequency of outcome factor in the population (p): 26%+/-5 [30] Con dence limits as % of 100(absolute +/-%) (d): 5%…”

Section: Sample Size Determinationmentioning

confidence: 99%

See 3 more Smart Citations

Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.

Woldu¹,

Minzi²,

Shibeshi³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

COVID-19-Induced Stroke and the Potential of Using Mesenchymal Stem Cells-Derived Extracellular Vesicles in the Regulation of Neuroinflammation

et al. 2022

View full text Add to dashboard Cite

Ischemic stroke (IS) is a known neurological complication of COVID-19 infection, which is associated with high mortality and disability. Following IS, secondary neuroinflammation that occurs can play both harmful and beneficial roles and lead to further injury or repair of damaged neuronal tissue, respectively. Since inflammation plays a pivotal role in the pathogenesis of COVID-19-induced stroke, targeting neuroinflammation could be an effective strategy for modulating the immune responses following ischemic events. Numerous investigations have indicated that the application of mesenchymal stem cells-derived extracellular vesicles (MSC-EVs) improves functional recovery following stroke, mainly through reducing neuroinflammation as well as promoting neurogenesis and angiogenesis. Therefore, MSC-EVs can be applied for the regulation of SARS-CoV-2-mediated inflammation and the management of COVID-19- related ischemic events. In this study, we have first described the advantages and disadvantages of neuroinflammation in the pathological evolution after IS and summarized the characteristics of neuroinflammation in COVID-19-related stroke. Then, we have discussed the potential benefit of MSC-EVs in the regulation of inflammatory responses after COVID-19-induced ischemic events.

show abstract

Factors associated with coronary artery disease among people living with human immunodeficiency virus: Results from the Colombian HIV/AIDS registry

Urina-Jassir,

Patiño-Aldana,

Herrera-Parra

et al. 2023

International Journal of Cardiology Cardiovascular Risk and Pre

View full text Add to dashboard Cite

Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review

Cited by 13 publications

References 81 publications

Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.

Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.

COVID-19-Induced Stroke and the Potential of Using Mesenchymal Stem Cells-Derived Extracellular Vesicles in the Regulation of Neuroinflammation

Factors associated with coronary artery disease among people living with human immunodeficiency virus: Results from the Colombian HIV/AIDS registry

Contact Info

Product

Resources

About